These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 21030348)
1. Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials. Offidani M; Leoni P; Corvatta L; Polloni C; Gentili S; Liberati AM; Pulini S; Gozzetti A; Ballanti S; Nozzoli C; Palumbo A Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):353-60. PubMed ID: 21030348 [TBL] [Abstract][Full Text] [Related]
2. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials. Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306 [TBL] [Abstract][Full Text] [Related]
4. Management of older patients with multiple myeloma. Gay F; Palumbo A Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387 [TBL] [Abstract][Full Text] [Related]
6. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. Morgan G Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634 [TBL] [Abstract][Full Text] [Related]
7. [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy]. Takeda Y; Sakaida E; Nakaseko C Nihon Rinsho; 2015 Jan; 73(1):130-6. PubMed ID: 25626318 [TBL] [Abstract][Full Text] [Related]
8. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Palumbo A; Attal M; Roussel M Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441 [TBL] [Abstract][Full Text] [Related]
9. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ; Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma. Manochakian R; Miller KC; Chanan-Khan AA Clin Lymphoma Myeloma; 2007 Jan; 7(4):266-71. PubMed ID: 17324333 [TBL] [Abstract][Full Text] [Related]
11. Treatment options for relapsed and refractory multiple myeloma. Lonial S; Mitsiades CS; Richardson PG Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442 [TBL] [Abstract][Full Text] [Related]